Hello guest, Register  |  Sign In
Virologica Sinica, 33 (3) : 227, 2018
Research Article
Evaluation of Epstein-Barr Virus Salivary Shedding in HIV/AIDS Patients and HAART Use: A Retrospective Cohort Study
1 Center of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated to Jiangnan University, Wuxi 214016, China
2 Wuxi Institute of Hepatology, The Fifth People's Hospital of Wuxi, Affiliated to Jiangnan University, Wuxi 214016, China
3 The International Joint Research Laboratory for Infection and Immunity(China-Germany), The Fifth People's Hospital of Wuxi, Affiliated to Jiangnan University, Wuxi 214016, China
4 Wuxi Red Ribbon Care Center of China Red Cross, The Fifth People's Hospital of Wuxi, Affiliated to Jiangnan University, Wuxi 214016, China
5 The International Joint Research Laboratory for Infection and Immunity(China-Germany), Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China
6 Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
 Correspondence: luhongzhou@fudan.edu.cn;huanglihua1964@sina.com
(778.96KB)  
Abstract
Little data is available on the evaluation of the occurrence rates of Epstein-Barr virus (EBV) in saliva and relationship with highly active antiretroviral therapy (HAART) use in HIV/AIDS patients in China. We conducted a retrospective cohort study of EBV serological tests for HIV/AIDS patients who were treated in the hospitals for infectious diseases in Wuxi and Shanghai, China from May 2016 to April 2017. The EBV-seropositive samples were identified by ELISA. EBV-specific primers and probes were used for the quantitative detection of viralDNAfrom saliva via quantitativereal-time polymerase chainreaction. CD4 cell counts of the HIV/ AIDS patientswere detected by a flow cytometry.A total of 372HIV/AIDS patients were ultimately selected and categorizedfor this retrospective cohort study. For EBV IgG and IgM, the HIV/AIDS HAART use (H) and non-HAART use (NH) groups had significantly higher seropositive rates than the HIV-negative control group. The HIV/AIDS (NH) group had the highest seropositive rate (IgG, 94.27%; IgM, 68.98%) and the highest incidence of EBV reactivation or infection. For salivary EBV DNA-positive rates and quantities, the HIV/AIDS (H) (73.69%) and the HIV/AIDS (NH) (100%) groups showed significantly higher values than the HIV-negative control group(35.79%,> twofold).Further,the salivaryEBVDNA-negative population hadsignificantly higher CD4 cell counts than the EBV DNA-positive population in the HIV/AIDS (H) group and the HIV/AIDS (NH) groups. Thus, HAART use is beneficial in decreasing the EBV salivary shedding in HIV/AIDS patients and indirectly decreases EBV transmission risk.
Received: 25 Oct 2017  Accepted: 9 Mar 2018  Published online: 13 Apr 2018
Home |  Resources |  About Us |  Support |  Contact Us |  Privacy |  Powered by CanSpeed | 
Copyright © 2015 Virologica Sinica. All rights reserved